NicOx SA has decided to withdraw its European marketing authorisation application for naproxcinod, a candidate drug for osteoarthritis, following feedback from the CHMP that more data would be required in order to get a positive opinion. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
